Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Pilot Study to evaLuate the Role of High-dose rAnbizumab (2.0mg) in the Management of AMD in Patients With perSistent/recurrenT Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Vitreous -Retina- Macula Consultants of New York.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by:
Vitreous -Retina- Macula Consultants of New York
ClinicalTrials.gov Identifier:
NCT01115556
First received: April 30, 2010
Last updated: December 14, 2011
Last verified: May 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2011
  Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)